US3773946A - Triglyceride-lowering compositions and methods - Google Patents
Triglyceride-lowering compositions and methods Download PDFInfo
- Publication number
- US3773946A US3773946A US00193170A US3773946DA US3773946A US 3773946 A US3773946 A US 3773946A US 00193170 A US00193170 A US 00193170A US 3773946D A US3773946D A US 3773946DA US 3773946 A US3773946 A US 3773946A
- Authority
- US
- United States
- Prior art keywords
- acid
- tetramethyldecanedioic
- methods
- compositions
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
Definitions
- the present invention relates to pharmaceutical compositions possessing serum triglyceride-lowering activity, and to methods for lowering serum triglyceride levels, said compositions and methods employing certain alkanedioic acids and salts and alkyl esters thereof.
- the invention relates to pharmaceutical compositions and methods employing compounds which can be represented by the formula in which n represents 6, 7, 8, 9, or and each of R and R represents hydrogen, a salt-forming cation, or a lower alkyl radical.
- the lower alkyl radicals are those containing not more than 8 carbon atoms.
- the salt-forming cations are preferably the pharmaceutically-acceptable cations of alkali metals, alkaline earth metals, ammonium, and substituted ammonium.
- compositions are produced by formulating a compound of the foregoing formula (as an active ingredient) in dosage unit form with a pharmaceutical carrier.
- dosage unit forms are tablets, capsules, lozenges, and pills; as well as powders and aqueous and non-aqueous solutions and suspensions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses by such means as measurement into a teaspoon or other standard container.
- suitable pharmaceutical carriers are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch; cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol; glycerine, sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline; and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations.
- the compositions ice of the invention can also contain other components such as coloring agents, flavoring agents, 'and/ or preservatives. These materials, if present, are usually used in relatively small amounts.
- the compositions can, if desired, also contain
- compositions of the invention can be varied within Wide limits but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primarily liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present.
- the compositions of the invention preferably contain from 20 to 1,000 mg. of the active ingredient per dosage unit so that the entire amount to be administered during a day can be made up from a reasonable number of dosage units.
- the compounds of the foregoing formula are administered for the purpose of lowering serum triglyceride levels.
- the aforementioned compounds and compositions containing the same can be administered either orally or parenterally, in dosage unit form, with the dose adjusted to the needs and tolerances of the individual patient. Oral administration is preferred.
- the usual human dosage range is from 50 to 2,000 mg. per day, preferably 100 to 500 mg. per day, optionally in divided portions. Treatment is continued while satisfactory control of the serum triglyceride level is maintained without undesired side-effects.
- the methods of the invention produce a lowering of the serum triglyceride level.
- the aforementioned compounds and compositions especially when they are administered at a relatively high dosage, also produce a lowering of the serum cholesterol level.
- the lowering of serum triglycerides is a characteristic feature of the invention and the lowering of serum cholesterol is an incidental feature.
- the eifectiveness of the aforementioned compounds and compositions in lowering serum triglycerides can be demonstrated by standard methods. For example, male rats weighing 200-250 g. are maintained on a normal pellet diet. Each animal in a treatment group is given a daily oral dose of a test compound for 7 days. An untreated control group is also maintained. At the end of the 7-day test period the animals are weighed and sacrificed, and the serum cholesterol and serum triglycerides are determined from blood samples taken from the vena cava. The methods used are described in Journal of Laboratory and Clinical Medicine, 50, 318 (1957) and Journal of Laboratory and Clinical Medicine, 50, 152 (1957).
- the test compound is considered to exhibit a side effect if the weight of the animals in the treatment group is significantly less than the weight of the animals in the control group.
- 2,2,9,9-tetramethyldecanedioic acid at 5 mg./kg. per day for 7 days produced a 44% reduction of serum triglycerides with no eifect on serum cholesterol or weight of the animals, relative to the untreated control group.
- 2,2,9,9-tetramethyldecanedioic acid, diethyl ester at mg./kg. per day for 7 days produced a 74% reduction of serum triglycerides with no effect on serum cholesterol or weight of the animals, relative to the untreated control group.
- compositions and methods of the invention are those employing an a,a,a',a'-telramethylalkanedioic acid of the formula or a cationic salt thereof; where n is as defined before and consequently represents 6, 7, 8, 9, or 10.
- the alkanedioic acids and a method of preparation have been described in Journal of the American Chemical Society, 73, 136 (1951).
- the alkanedioic acids, their salts and esters can also be prepared by reacting isobutyric acid or an ester thereof with a polymethylene dihalide in the presence of a strong base in an anhydrous medium, optionally followed by acidification, as illustrated in greater detail hereinafter.
- the alkanedioic acid esters can also be prepared by esterifying the alkanedioic acids, typically by reaction With a lower alkanol in the presence of a mineral acid or strong organic acid.
- the alkanedioic acid salts can be prepared from the alkanedioic acids by reaction with any of a large number of bases.
- Example 1 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Lactose 960 Magnesium stearate 40 The mixture is blended in a twin-shell blender and filled into No. 4 hard gelatin capsules. Each capsule is filled with 200 mg. of the powder mixture and contains 100 mg. of 2,2,9,9-tetramethyldecanedioic acid. Yield equals approximately 10,000 capsules.
- Example 2 Ingredient: Quantity, g. 2,2,11,11-tetramethyldodecanedioic acid 1,000 Lactose 960 Magnesium stearate 40 2,2,9,9-tetramethyldecanedioic acid, disodium salt. 2,2,9,9-tetramethyldecanedioic acid, dipotassium salt. 2,2,9,9-tetramethyldecanedioic acid, dicholine salt. 2,2,12,12-tetramethyltridecanedioic acid. 2,2,13,13-tetramethyltetradecanedioic acid.
- Example 3 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Lactose 800 Magnesium stearate '35 The mixture is blended and filled into No. 3 hard gelatin capsules, filling each capsule with 367 mg. of the powder mixture. Yield equals approximately 5,000 capsules, each containing 200 mg. of 2,2,9,9-tetramethyldecanedioic acid.
- Example 4 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Propylene glycol 1,000
- filled gelatin capsules are obtained by substituting 1,000 g. of either of the following substances for the 2,2,9,9-tetramethyldecanedioic acid in the foregoing procedure:
- Example 5 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid g 3,000 Lactose g 750 Corn starch g 300 Gelatin .g Water .cc 1,000 Magnesium stearate g 20
- the 2,2,9,9-tetramethyldecanedioic acid, lactose, and g. of the corn starch are blended and granulated with a solution of the gelatin in the Water.
- the wet granulation is screened, dried, and re-screened.
- the resulting dried granulation is blended with the magnesium stearate and the remaining 150 g. of corn starch, and the mixture is compressed into 698 mg. tablets using 75 inch standard concave punches. Yield equals approximately 6,000 tablets, each containing 500 mg. of 2,2,9,9tetramethyldecanedioic acid.
- Example 6 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid (micronized) g 4 Polyoxyethylene sorbitan monostearate cc 0.1 Sodium carboxymethyl cellulose g 0.3 Complex magnesium-aluminum silicate g 0.5 Sugar g 10 Glycerin cc 2 Sodium benzoate g 0.5 Sodium citrate g 0.2 Approved red dye mg 1 Imitation cherry fiavor cc 0.02 Citric acid, to make pH 4.0.
- the polyoxyethylene sorbitan monostearate can be a product such as polysorbate 60 or Tween 60.
- the complex magnesium-aluminum silicate is a gel-forming agent.
- a product such as Veegum H.V. can be used. This substance is hydrated overnight in 10 cc. of distilled water.
- a mixture is prepared from the polyoxyethylene sorbitan monostearate, imitation cherry flavor, 30 cc. of distilled water, and the 2,2,9,9-tetramethyldecanedioic acid and passed through a homogenizer.
- the sugar, glycerin, sodium citrate, sodium benzoate, and sodium carboxymethyl cellulose are added, followed by hydated complex magnesium-aluminum silicate and a solutionof the red dye in 2 cc. of water.
- the resulting suspension is homogenized, adjusted to pH 4.0 with citric acid, and diluted to a final volume of 100 cc. with distilled water.
- a 5 cc. oral dosage unit of this suspension contains 200 mg. of 2,2,9,Q-tetramethyldecanedioic acid.
- the red dye and imitation cherry flavor can be omitted or replaced by other coloring and flavoring agents.
- Example 7 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid g 20 Polyethylene glycol cc 50 Benzyl alcohol cc 4 Sodium hydroxide 10% solution, to make pH 8.0. Hydrochloric acid 10% solution, to make pH 8.0. Sterile distilled Water, to make 200 cc.
- the polyethylene glycol used in this formulation can be a material such as polyethylene glycol 400.
- a solution is prepared by dissolving 2,2,9,9-tetramethyldecanedioic acid in 100 cc. of sodium hydroxide solution.
- the polyethylene glycol and the benzyl alcohol are added and the pH is adjusted to 8.0 using 10% sodium hydroxide and 10% hydrochloric acid.
- the solution is sterilized by filtration using a sterilized millipore filter membrane and a microfiber glass pre-filter disc.
- Equipment suitable for this purpose is a type SS (0.22 micron pore size) millipore filter membrane and a type AP-20 microfiber glass pre-filter disc.
- the filtrate is collected in a sterile receiving vessel and aseptically filled into round amber glass vials, filling each vial with 2 cc. of the solution and sealing the vial.
- the resulting solution for parenteral administration contains 100 mg. of 2,2,9,9-tetramethyldecanedioic acid per cc.
- the mixture is stirred for 10 minutes at 0-10 C., for 30 minutes at room temperature, again cooled to 010 C., and treated with a solution of 36.6 g. of 1,6-dibromohexane in 50 ml. of anhydrous tetrahydrofuran. It is then stirred overnight at room temperature, cooled to 0 C., and cautiously diluted with 500 m1. of water.
- the aqueous phase is separated, washed with ether, and acidified with hydrochloric acid.
- the acidified mixture is extracted with ether and the ether extract is washed with water, dried, and evaporated to give a residue of 2,2,9,9-tetramethyldecanedioic acid; M.P. 116-117.5 C. following crystallization from acetonitrile.
- the product is 2,2,11,1l-tetramethyldodecanedioic acid; M.P. 92.5- 95 C.
- Salts with pharmaceutically-acceptable cations are obtained by reacting any of the alkanedioic acids with a base such as sodium hydroxide, potassium hydroxide, potassium carbonate, calcium hydroxide, ammonia, diethylamine, Z-aminoethanol, or choline.
- a base such as sodium hydroxide, potassium hydroxide, potassium carbonate, calcium hydroxide, ammonia, diethylamine, Z-aminoethanol, or choline.
- a suspension of 5.2 g. of 2,2,9,9-tetramethyldecanedioic acid in 30 ml. of water is treated with 37 ml. of 1 N sodium hydroxide and then with 20 ml. of methanol.
- the mixture is concentrated to onethird its original volume, diluted with 100 ml. of water, concentrated to two-thirds volume, and freeze-dried to give a residue of 2,2,9,9-tetramethyldecanedioic acid,
- disodium salt l 3y substituting an equivalent amount of potassium hydroxide for the sodium hydroxide, the product is 2,2,9,9-tetramethyldecanedioic acid, dipotassium salt. By substituting an equivalent amount of choline for the sodium hydroxide, the product is 2,2,9,9-tetramethyldecanedioic acid, dicholine salt.
- a mixture of 50 g. of 2,2,9,9-tetramethyldecanedioic acid, 1.2 g. of p-toluensulfonic acid monohydrate, 45 ml. of ethanol, and 300 ml. of toluene is heated at reflux for 36 hours, with continuous removal of the water formed in the reaction.
- the mixture is cooled, washed with dilute sodium hydroxide solution and with water, dried over magnesium sulfate, and concentrated to dryness under reduced pressure to give a residue of 2,2,9,9-tetramethyl decanedioic acid, diethyl ester.
- the product is distilled in vacuo; B.P. 134-136" C. at 1 mm.
- the product is 2,2,9,9-tetramethyl decanedioic acid, diisopropyl ester.
- the product is 2,2,9,9-tetramethyldecanedioic acid, dibutyl ester.
- the product is 2,2,9,9-tetramethyldecanedioic acid, dioctyl ester; B.P. higher than 180 C. at 0.05
- a pharmaceutical composition in dosage unit form possessing serum triglyceride-lowering activity and suitable for oral administration comprising a solid pharmaceutical carrier and 20 to 1,000 mg. per dosage unit of a compound of the formula CH CH where n is 6, 7, 8, 9, or 10; and R and R ⁇ are selected from the group consisting of hydrogen, pharmaceuticallyacceptable salt-forming cations, and lower alkyl.:
- composition of claim 1 in the form of a capsule or tablet in which the compound of the indicated formula is 2,2,9,9-tetramethyldecanedioic acid.
- composition of claim 2 containing mg. of 2,2,9,9-tetramethyldecanedioic acid.
- a method for lowering serum triglyceride levels which comprises administering a compound of the formula 0 CH (Ill-l O CH3 CH3 orally or parenterally in humans in need thereof in a dose of at least 50 mg. per day; where n is 6, 7, 8, 9, or 10; and R and R are selected from the group consisting of hydrogen, pharmaceutically-acceptable salt-forming cations, and lower alkyl.
Abstract
PHARMACEUTICAL COMPOSITIONS COMPRISING A PHARMACEUTICAL CARRIER AND AN A,A,A'',A''-TETRAMETHYLALKANEDOIC ACID HAVING A TOTAL OF 14 TO 18 CARBON ATOMS, OR A SALT OR ALKYL ESTER OF SUCH AN ALKANEDIOIC ACID. METHODS FOR THE LOWERING OF SERUM TRIGLYCERIDE LEVELS BY ADMINISTERING AN A,A,A'',A''-TETRAMETHYLALKANEDOIC ACID HAVING A TOTAL OF 14 TO 18 CARBON ATOMS, OR A SALT OR ALKYL ESTER OF SUCH AN ALKANEDIOIC ACID.
Description
United States Patent O 3,773,946 TRIGLYCERIDE-LOWERING COMPOSITIONS AND METHODS Paul L. Creger, Ann Arbor, Mich., assignor to Parke, Davis & Company, Detroit, Mich.
No Drawing. Continuation-in-part of abandoned application Ser. No. 854,756, Sept. 2, 1969. This application Oct. 27, 1971, Ser. No. 193,170
Int. Cl. A61k 27/00 US. Cl. 424-318 6 Claims ABSTRACT OF THE DISCLOSURE Pharmaceutiml compositions comprising a pharmaceutical carrier and an a,a,u,a'-tetramethylalkanedioic acid having a total of 14 to 18 carbon atoms, or a salt or alkyl ester of such an alkanedioic acid. Methods for the lowering of serum triglyceride levels by administering an a,u,a,u'-tetramethylalkanedioic acid having a total of 14 to 18 carbon atoms, or 'a salt or alkyl ester of such an alkanedioic acid.
CROSS REFERENCE TO RELATED APPLICATION This is a continuation-in-part of co-pending application Ser. No. 854,756, filed Sept. 2, 1969, now abandoned.
SUMMARY AND DETAILED DESCRIPTION The present invention relates to pharmaceutical compositions possessing serum triglyceride-lowering activity, and to methods for lowering serum triglyceride levels, said compositions and methods employing certain alkanedioic acids and salts and alkyl esters thereof.
More particularly, the invention relates to pharmaceutical compositions and methods employing compounds which can be represented by the formula in which n represents 6, 7, 8, 9, or and each of R and R represents hydrogen, a salt-forming cation, or a lower alkyl radical. The lower alkyl radicals are those containing not more than 8 carbon atoms. The salt-forming cations are preferably the pharmaceutically-acceptable cations of alkali metals, alkaline earth metals, ammonium, and substituted ammonium.
In accordance with the invention, pharmaceutical compositions are produced by formulating a compound of the foregoing formula (as an active ingredient) in dosage unit form with a pharmaceutical carrier. Some examples of dosage unit forms are tablets, capsules, lozenges, and pills; as well as powders and aqueous and non-aqueous solutions and suspensions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses by such means as measurement into a teaspoon or other standard container. Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch; cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol; glycerine, sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline; and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations. The compositions ice of the invention can also contain other components such as coloring agents, flavoring agents, 'and/ or preservatives. These materials, if present, are usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents.
The percentage of the active ingredient in the foregoing compositions can be varied within Wide limits but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primarily liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present. The compositions of the invention preferably contain from 20 to 1,000 mg. of the active ingredient per dosage unit so that the entire amount to be administered during a day can be made up from a reasonable number of dosage units.
Also in accordance with the invention, the compounds of the foregoing formula are administered for the purpose of lowering serum triglyceride levels. The aforementioned compounds and compositions containing the same can be administered either orally or parenterally, in dosage unit form, with the dose adjusted to the needs and tolerances of the individual patient. Oral administration is preferred. The usual human dosage range is from 50 to 2,000 mg. per day, preferably 100 to 500 mg. per day, optionally in divided portions. Treatment is continued while satisfactory control of the serum triglyceride level is maintained without undesired side-effects.
The methods of the invention, as explained above, produce a lowering of the serum triglyceride level. In many cases the aforementioned compounds and compositions, especially when they are administered at a relatively high dosage, also produce a lowering of the serum cholesterol level. The lowering of serum triglycerides is a characteristic feature of the invention and the lowering of serum cholesterol is an incidental feature.
The eifectiveness of the aforementioned compounds and compositions in lowering serum triglycerides can be demonstrated by standard methods. For example, male rats weighing 200-250 g. are maintained on a normal pellet diet. Each animal in a treatment group is given a daily oral dose of a test compound for 7 days. An untreated control group is also maintained. At the end of the 7-day test period the animals are weighed and sacrificed, and the serum cholesterol and serum triglycerides are determined from blood samples taken from the vena cava. The methods used are described in Journal of Laboratory and Clinical Medicine, 50, 318 (1957) and Journal of Laboratory and Clinical Medicine, 50, 152 (1957). The test compound is considered to exhibit a side effect if the weight of the animals in the treatment group is significantly less than the weight of the animals in the control group. In a representative determination, 2,2,9,9-tetramethyldecanedioic acid at 5 mg./kg. per day for 7 days produced a 44% reduction of serum triglycerides with no eifect on serum cholesterol or weight of the animals, relative to the untreated control group. 2,2,9,9-tetramethyldecanedioic acid, diethyl ester at mg./kg. per day for 7 days produced a 74% reduction of serum triglycerides with no effect on serum cholesterol or weight of the animals, relative to the untreated control group. i
The preferred pharmaceutical compositions and methods of the invention are those employing an a,a,a',a'-telramethylalkanedioic acid of the formula or a cationic salt thereof; where n is as defined before and consequently represents 6, 7, 8, 9, or 10.
Many of the compounds employed in the compositions and methods of the invention are old. They can all be prepared in a number of different Ways. The alkanedioic acids and a method of preparation have been described in Journal of the American Chemical Society, 73, 136 (1951). The alkanedioic acids, their salts and esters can also be prepared by reacting isobutyric acid or an ester thereof with a polymethylene dihalide in the presence of a strong base in an anhydrous medium, optionally followed by acidification, as illustrated in greater detail hereinafter. The alkanedioic acid esters can also be prepared by esterifying the alkanedioic acids, typically by reaction With a lower alkanol in the presence of a mineral acid or strong organic acid. The alkanedioic acid salts can be prepared from the alkanedioic acids by reaction with any of a large number of bases.
The invention is illustrated by the following examples.
Example 1 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Lactose 960 Magnesium stearate 40 The mixture is blended in a twin-shell blender and filled into No. 4 hard gelatin capsules. Each capsule is filled with 200 mg. of the powder mixture and contains 100 mg. of 2,2,9,9-tetramethyldecanedioic acid. Yield equals approximately 10,000 capsules.
Example 2 Ingredient: Quantity, g. 2,2,11,11-tetramethyldodecanedioic acid 1,000 Lactose 960 Magnesium stearate 40 2,2,9,9-tetramethyldecanedioic acid, disodium salt. 2,2,9,9-tetramethyldecanedioic acid, dipotassium salt. 2,2,9,9-tetramethyldecanedioic acid, dicholine salt. 2,2,12,12-tetramethyltridecanedioic acid. 2,2,13,13-tetramethyltetradecanedioic acid.
Example 3 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Lactose 800 Magnesium stearate '35 The mixture is blended and filled into No. 3 hard gelatin capsules, filling each capsule with 367 mg. of the powder mixture. Yield equals approximately 5,000 capsules, each containing 200 mg. of 2,2,9,9-tetramethyldecanedioic acid.
Example 4 Ingredient: Quantity, g. 2,2,9,9-tetramethyldecanedioic acid 1,000 Propylene glycol 1,000
The above ingredients are blended and filled into soft gelatin capsules, filling each capsule with 400 mg. of the mixture. Yield equals approximately 5,000 capsules, each containing 200 mg. of 2,2,9,9-tetramethyldecanedioic acid.
Similarly, filled gelatin capsules are obtained by substituting 1,000 g. of either of the following substances for the 2,2,9,9-tetramethyldecanedioic acid in the foregoing procedure:
2,2,9,9-tetramethyldecanedioic acid, diethyl ester. 2,2,9,9-tetramethyldecanedioic acid, diisopropyl ester. 2,2,9,9-tetramethyldecanedioic acid, dibutyl ester. 2,2,9,9-tetramethyldecanedioic acid, dioctyl ester.
Example 5 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid g 3,000 Lactose g 750 Corn starch g 300 Gelatin .g Water .cc 1,000 Magnesium stearate g 20 The 2,2,9,9-tetramethyldecanedioic acid, lactose, and g. of the corn starch are blended and granulated with a solution of the gelatin in the Water. The wet granulation is screened, dried, and re-screened. The resulting dried granulation is blended with the magnesium stearate and the remaining 150 g. of corn starch, and the mixture is compressed into 698 mg. tablets using 75 inch standard concave punches. Yield equals approximately 6,000 tablets, each containing 500 mg. of 2,2,9,9tetramethyldecanedioic acid.
Example 6 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid (micronized) g 4 Polyoxyethylene sorbitan monostearate cc 0.1 Sodium carboxymethyl cellulose g 0.3 Complex magnesium-aluminum silicate g 0.5 Sugar g 10 Glycerin cc 2 Sodium benzoate g 0.5 Sodium citrate g 0.2 Approved red dye mg 1 Imitation cherry fiavor cc 0.02 Citric acid, to make pH 4.0.
Distilled water, to make 100 cc.
The polyoxyethylene sorbitan monostearate can be a product such as polysorbate 60 or Tween 60. The complex magnesium-aluminum silicate is a gel-forming agent. A product such as Veegum H.V. can be used. This substance is hydrated overnight in 10 cc. of distilled water. A mixture is prepared from the polyoxyethylene sorbitan monostearate, imitation cherry flavor, 30 cc. of distilled water, and the 2,2,9,9-tetramethyldecanedioic acid and passed through a homogenizer. With vigorous stirring, the sugar, glycerin, sodium citrate, sodium benzoate, and sodium carboxymethyl cellulose are added, followed by hydated complex magnesium-aluminum silicate and a solutionof the red dye in 2 cc. of water. The resulting suspension is homogenized, adjusted to pH 4.0 with citric acid, and diluted to a final volume of 100 cc. with distilled water. A 5 cc. oral dosage unit of this suspension contains 200 mg. of 2,2,9,Q-tetramethyldecanedioic acid. If desired, the red dye and imitation cherry flavor can be omitted or replaced by other coloring and flavoring agents.
By the foregoing procedure, with the substitution of 4 g. of micronized 2,2,10,10-tetramethylundecanedioic acid for the 2,2,9,9-tetramethyldecanedioic acid, a suspension containing 200 mg. of 2,2,10,10-tetramethylundecanedioic acid per 5 cc. oral dosage unit is obtained.
Example 7 Ingredient: Quantity 2,2,9,9-tetramethyldecanedioic acid g 20 Polyethylene glycol cc 50 Benzyl alcohol cc 4 Sodium hydroxide 10% solution, to make pH 8.0. Hydrochloric acid 10% solution, to make pH 8.0. Sterile distilled Water, to make 200 cc.
The polyethylene glycol used in this formulation can be a material such as polyethylene glycol 400. A solution is prepared by dissolving 2,2,9,9-tetramethyldecanedioic acid in 100 cc. of sodium hydroxide solution. The polyethylene glycol and the benzyl alcohol are added and the pH is adjusted to 8.0 using 10% sodium hydroxide and 10% hydrochloric acid. The solution is sterilized by filtration using a sterilized millipore filter membrane and a microfiber glass pre-filter disc. Equipment suitable for this purpose is a type SS (0.22 micron pore size) millipore filter membrane and a type AP-20 microfiber glass pre-filter disc. The filtrate is collected in a sterile receiving vessel and aseptically filled into round amber glass vials, filling each vial with 2 cc. of the solution and sealing the vial. The resulting solution for parenteral administration contains 100 mg. of 2,2,9,9-tetramethyldecanedioic acid per cc.
PREPARATION OF TETRAMETHY'LALKANE- DIOIC ACIDS, SALTS, AND ESTERS At 010 C., 375 ml. of a solution of n-butyllithium in heptane (1.6 millimoles/ml.) is added with stirring to a solution of 61 g. of diisopropylamine in 300 ml. of anhydrous tetrahydrofuran. The cold mixture is stirred for 10 more minutes and then treated with a solution of 26.4 g. of isobutyric acid in 25 ml. of anhydrous tetrahydrofuran, added over a period of 20 minutes. The mixture is stirred for 10 minutes at 0-10 C., for 30 minutes at room temperature, again cooled to 010 C., and treated with a solution of 36.6 g. of 1,6-dibromohexane in 50 ml. of anhydrous tetrahydrofuran. It is then stirred overnight at room temperature, cooled to 0 C., and cautiously diluted with 500 m1. of water. The aqueous phase is separated, washed with ether, and acidified with hydrochloric acid. The acidified mixture is extracted with ether and the ether extract is washed with water, dried, and evaporated to give a residue of 2,2,9,9-tetramethyldecanedioic acid; M.P. 116-117.5 C. following crystallization from acetonitrile.
By the foregoing procedure, with the substitution of another polymethylene dihalide for the 1,6-dibromohexane, the following additional products are obtained.
From 40.8 g. of 1,8-dibromooctane, the product is 2,2,11,1l-tetramethyldodecanedioic acid; M.P. 92.5- 95 C.
From 42.9 g. of 1,9-dibromononane, the product is 2,2, 12,lZ-tetramethyltridecanedioic acid; M.P. 70-72" C.
From 45.0 g. of 1,10-dibromodecane, the product is 2,2,13,13-tetramethyltetradecanedioic acid; M.P. 86- 88 C.
With stirring, 12.7 g. of sodium hydride and then 27.8 g. of isobutyric acid are added to a solution of 42 ml. of diisopropylamine in 300 ml. of anhydrous tetrahydrofuran. The mixture is heated at reflux for 45 minutes, cooled to 0 C., and treated with 213.5 ml. of a solution of n-butyllithium in heptane (1.4 millimoles/ml.). The
mixture is then stirred for 30 minutes at room tempera ture, cooled to 0 0., treated with 25.4 g. of 1,7-dichloroheptane, and stirred overnight at room temperature. It is then hydrolyzed and the product isolated as described above to give 2,2,10,10-tetramethylundecanedioic acid; M.P. 7577 C. following crystallization from acetonitrile.
Salts with pharmaceutically-acceptable cations are obtained by reacting any of the alkanedioic acids with a base such as sodium hydroxide, potassium hydroxide, potassium carbonate, calcium hydroxide, ammonia, diethylamine, Z-aminoethanol, or choline. For example, a suspension of 5.2 g. of 2,2,9,9-tetramethyldecanedioic acid in 30 ml. of water is treated with 37 ml. of 1 N sodium hydroxide and then with 20 ml. of methanol. The mixture is concentrated to onethird its original volume, diluted with 100 ml. of water, concentrated to two-thirds volume, and freeze-dried to give a residue of 2,2,9,9-tetramethyldecanedioic acid,
disodium salt. l 3y substituting an equivalent amount of potassium hydroxide for the sodium hydroxide, the product is 2,2,9,9-tetramethyldecanedioic acid, dipotassium salt. By substituting an equivalent amount of choline for the sodium hydroxide, the product is 2,2,9,9-tetramethyldecanedioic acid, dicholine salt.
A mixture of 50 g. of 2,2,9,9-tetramethyldecanedioic acid, 1.2 g. of p-toluensulfonic acid monohydrate, 45 ml. of ethanol, and 300 ml. of toluene is heated at reflux for 36 hours, with continuous removal of the water formed in the reaction. The mixture is cooled, washed with dilute sodium hydroxide solution and with water, dried over magnesium sulfate, and concentrated to dryness under reduced pressure to give a residue of 2,2,9,9-tetramethyl decanedioic acid, diethyl ester. For purification the product is distilled in vacuo; B.P. 134-136" C. at 1 mm.
Similarly, with the substitution of 59 ml. of isopropyl alcohol for the ethanol, the product is 2,2,9,9-tetramethyl decanedioic acid, diisopropyl ester.
Similarly, with the substitution of 71 ml. of l-butanol for the ethanol, the product is 2,2,9,9-tetramethyldecanedioic acid, dibutyl ester.
Similarly, with the substitution of 122 ml. of l-octanol for the ethanol, the product is 2,2,9,9-tetramethyldecanedioic acid, dioctyl ester; B.P. higher than 180 C. at 0.05
I claim:
1. A pharmaceutical composition in dosage unit form possessing serum triglyceride-lowering activity and suitable for oral administration, comprising a solid pharmaceutical carrier and 20 to 1,000 mg. per dosage unit of a compound of the formula CH CH where n is 6, 7, 8, 9, or 10; and R and R} are selected from the group consisting of hydrogen, pharmaceuticallyacceptable salt-forming cations, and lower alkyl.:
'2. The composition of claim 1 in the form of a capsule or tablet in which the compound of the indicated formula is 2,2,9,9-tetramethyldecanedioic acid.
3. The composition of claim 2 containing mg. of 2,2,9,9-tetramethyldecanedioic acid.
4. A method for lowering serum triglyceride levels which comprises administering a compound of the formula 0 CH (Ill-l O CH3 CH3 orally or parenterally in humans in need thereof in a dose of at least 50 mg. per day; where n is 6, 7, 8, 9, or 10; and R and R are selected from the group consisting of hydrogen, pharmaceutically-acceptable salt-forming cations, and lower alkyl.
5. The method of claim 4 wherein 2,2,9,9-tetramethyldecanedioic acid is administered.
6. The method of claim 5 wherein the administration is oral.
References Cited Journal of American Chemical Society, vol. 73 (1951), 136-141.
ALBERT T. MEYERS, Primary Examiner F. E. WADDELL, Assistant Examiner US. Cl. X.R. 424313
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85475669A | 1969-09-02 | 1969-09-02 | |
US19317071A | 1971-10-27 | 1971-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3773946A true US3773946A (en) | 1973-11-20 |
Family
ID=26888738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00193170A Expired - Lifetime US3773946A (en) | 1969-09-02 | 1971-10-27 | Triglyceride-lowering compositions and methods |
Country Status (1)
Country | Link |
---|---|
US (1) | US3773946A (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0081930A1 (en) * | 1981-12-15 | 1983-06-22 | Epis S.A. | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
WO1984003626A1 (en) * | 1983-03-22 | 1984-09-27 | Baxter Travenol Lab | Nutrient polyesters |
US4851439A (en) * | 1985-01-15 | 1989-07-25 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
EP0988274A1 (en) * | 1997-01-07 | 2000-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US20030236212A1 (en) * | 2002-04-10 | 2003-12-25 | Jean-Louis Dasseux | Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses |
US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US6699910B2 (en) | 2000-10-11 | 2004-03-02 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20040198814A1 (en) * | 2000-10-11 | 2004-10-07 | Dasseux Jean-Louis Henri | Ketone compounds and compositions for cholesterol management and related uses |
US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20040209847A1 (en) * | 2003-01-23 | 2004-10-21 | Dasseux Jean-Louis Henri | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US20050004196A1 (en) * | 2003-07-03 | 2005-01-06 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such |
US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US20050101561A1 (en) * | 2003-11-07 | 2005-05-12 | Tunac Josefino B. | HDL-boosting combination therapy complexes |
US20050101565A1 (en) * | 2002-07-03 | 2005-05-12 | Esperion Therapeutics, Inc. | Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders |
US20050192347A1 (en) * | 2003-12-23 | 2005-09-01 | Dasseux Jean-Louis H. | Urea and thiourea compounds and compositions for cholesterol management and related uses |
US20050277690A1 (en) * | 2004-06-09 | 2005-12-15 | Sircar Jagadish C | Small molecules for treatment of hypercholesterolemia and related diseases |
US20060009487A1 (en) * | 2004-06-09 | 2006-01-12 | Sircar Jagadish C | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
US20060205767A1 (en) * | 2004-10-20 | 2006-09-14 | Wong Norman C | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US20070004644A1 (en) * | 2004-06-09 | 2007-01-04 | Sircar Jagadish C | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
US20070203212A1 (en) * | 2002-08-22 | 2007-08-30 | Warner-Lambert Company | Method of treating osteoarthritis |
US20080188467A1 (en) * | 2007-02-01 | 2008-08-07 | Wong Norman C W | Compounds for the prevention and treatment of cardiovascular diseases |
WO2008147807A2 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US20090029987A1 (en) * | 2005-07-29 | 2009-01-29 | Resverlogix Corp. | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices |
US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
US8623897B2 (en) | 2010-09-20 | 2014-01-07 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
US9610251B2 (en) | 2011-11-01 | 2017-04-04 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US20190039989A1 (en) * | 2016-02-25 | 2019-02-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US11116739B2 (en) | 2015-03-16 | 2021-09-14 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease |
US11407705B2 (en) | 2019-06-21 | 2022-08-09 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
-
1971
- 1971-10-27 US US00193170A patent/US3773946A/en not_active Expired - Lifetime
Cited By (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0081930A1 (en) * | 1981-12-15 | 1983-06-22 | Epis S.A. | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US4634795A (en) * | 1981-12-15 | 1987-01-06 | Epis S.A. | Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US4689344A (en) * | 1981-12-15 | 1987-08-25 | Epis S.A. | Long-chain α,ω-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
WO1984003626A1 (en) * | 1983-03-22 | 1984-09-27 | Baxter Travenol Lab | Nutrient polyesters |
US4701443A (en) * | 1983-03-22 | 1987-10-20 | Baxter Travenol Laboratories, Inc. | Nutrient polyesters |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
US5451667A (en) * | 1985-01-15 | 1995-09-19 | Speiser; Peter P. | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
US4851439A (en) * | 1985-01-15 | 1989-07-25 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
EP2112134A1 (en) | 1997-01-07 | 2009-10-28 | Syndromex Ltd. | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
EP0988274A1 (en) * | 1997-01-07 | 2000-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
EP0988274A4 (en) * | 1997-01-07 | 2000-10-18 | Yissum Res Dev Co | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JP2001507713A (en) * | 1997-01-07 | 2001-06-12 | イッサム・リサーチ・アンド・ディベロープメント・カンパニー・オブ・ザ・ヘブルー・ユニヴァーシティ・オブ・エルサレム | Carboxylic acids and their derivatives and pharmaceutical compositions containing them |
KR100806928B1 (en) * | 1997-01-07 | 2008-02-22 | 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
KR100806927B1 (en) | 1997-01-07 | 2008-02-22 | 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
US20050004082A1 (en) * | 1999-04-01 | 2005-01-06 | Esperion Therapeutics, Inc. | Ether compounds |
US6459003B1 (en) | 1999-04-01 | 2002-10-01 | Esperion Therapeutics, Inc. | Ether compounds |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US6909014B2 (en) | 1999-04-01 | 2005-06-21 | Esperion Therapeutics, Inc. | Intermediates for the synthesis of ether compounds |
US20050119333A1 (en) * | 1999-04-01 | 2005-06-02 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US6506799B1 (en) | 1999-04-01 | 2003-01-14 | Esperion Therapeutics, Inc. | Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds |
US7192940B2 (en) | 1999-04-01 | 2007-03-20 | Esperion Therapeutics, Inc. | Ether compounds |
US6646170B2 (en) | 1999-04-01 | 2003-11-11 | Esperion Therapeutics, Inc. | Intermediates for the synthesis of ether compounds |
US6790953B2 (en) | 1999-04-01 | 2004-09-14 | Esperion Therapeutics, Inc. | Ether compounds |
US6831105B2 (en) | 1999-04-01 | 2004-12-14 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US7709515B2 (en) | 1999-04-01 | 2010-05-04 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US20100256209A1 (en) * | 1999-04-01 | 2010-10-07 | Esperion Therapeutics, Inc. | Compositions comprising ether compounds and pharmaceutical uses therefor |
US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6673780B2 (en) | 2000-10-11 | 2004-01-06 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20070149615A9 (en) * | 2000-10-11 | 2007-06-28 | Dasseux Jean-Louis H | Ketone compounds and compositions for cholesterol management and related uses |
US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US20040198814A1 (en) * | 2000-10-11 | 2004-10-07 | Dasseux Jean-Louis Henri | Ketone compounds and compositions for cholesterol management and related uses |
US6699910B2 (en) | 2000-10-11 | 2004-03-02 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20050020694A1 (en) * | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US20040192771A1 (en) * | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
US20030236212A1 (en) * | 2002-04-10 | 2003-12-25 | Jean-Louis Dasseux | Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses |
US20030236213A1 (en) * | 2002-04-10 | 2003-12-25 | Jean-Louis Dasseux | Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
US20050101565A1 (en) * | 2002-07-03 | 2005-05-12 | Esperion Therapeutics, Inc. | Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders |
US20070203212A1 (en) * | 2002-08-22 | 2007-08-30 | Warner-Lambert Company | Method of treating osteoarthritis |
US20050043278A1 (en) * | 2003-01-23 | 2005-02-24 | Dasseux Jean-Louis Henri | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7405226B2 (en) | 2003-01-23 | 2008-07-29 | Pfizer Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US20060229281A1 (en) * | 2003-01-23 | 2006-10-12 | Esperion Therapeutic, Inc. | Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol Management and Related Uses |
US8623915B2 (en) | 2003-01-23 | 2014-01-07 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US8497301B2 (en) | 2003-01-23 | 2013-07-30 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7119221B2 (en) | 2003-01-23 | 2006-10-10 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US20070179120A1 (en) * | 2003-01-23 | 2007-08-02 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US8309604B2 (en) | 2003-01-23 | 2012-11-13 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
JP2012097105A (en) * | 2003-01-23 | 2012-05-24 | Esperion Therapeutics Inc | Hydroxyl compound and composition for cholesterol management and related use |
US8153690B2 (en) | 2003-01-23 | 2012-04-10 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management |
US9000041B2 (en) | 2003-01-23 | 2015-04-07 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7335799B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US20080064661A1 (en) * | 2003-01-23 | 2008-03-13 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US9006290B2 (en) | 2003-01-23 | 2015-04-14 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US20110003860A1 (en) * | 2003-01-23 | 2011-01-06 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US10941095B2 (en) | 2003-01-23 | 2021-03-09 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US20080249166A1 (en) * | 2003-01-23 | 2008-10-09 | Esperion Therapeutics, Inc. | Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol Management |
EP2404890A1 (en) | 2003-01-23 | 2012-01-11 | Esperion Therapeutics Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US10118881B2 (en) | 2003-01-23 | 2018-11-06 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US10047028B2 (en) | 2003-01-23 | 2018-08-14 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US7576130B2 (en) | 2003-01-23 | 2009-08-18 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US20090247489A1 (en) * | 2003-01-23 | 2009-10-01 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
EP2402300A1 (en) | 2003-01-23 | 2012-01-04 | Esperion Therapeutics Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US8067466B2 (en) | 2003-01-23 | 2011-11-29 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management |
US9452964B2 (en) | 2003-01-23 | 2016-09-27 | Esperion Therapeutics, Inc. | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US20040214887A1 (en) * | 2003-01-23 | 2004-10-28 | Dasseux Jean-Louis Henri | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US9624152B2 (en) | 2003-01-23 | 2017-04-18 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US20040209847A1 (en) * | 2003-01-23 | 2004-10-21 | Dasseux Jean-Louis Henri | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
US7812199B2 (en) | 2003-01-23 | 2010-10-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
US7838554B2 (en) | 2003-01-23 | 2010-11-23 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
US20050004196A1 (en) * | 2003-07-03 | 2005-01-06 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such |
US20080248070A1 (en) * | 2003-11-07 | 2008-10-09 | Tunac Josefino B | HDL-Boosting Combination Therapy Complexes |
US8258125B2 (en) | 2003-11-07 | 2012-09-04 | Tunac Josefino B | HDL-boosting combination therapy complexes |
US20050101561A1 (en) * | 2003-11-07 | 2005-05-12 | Tunac Josefino B. | HDL-boosting combination therapy complexes |
US7390504B2 (en) | 2003-11-07 | 2008-06-24 | Jj Pharma, Inc. | HDL-boosting combination therapy complexes |
US20050192347A1 (en) * | 2003-12-23 | 2005-09-01 | Dasseux Jean-Louis H. | Urea and thiourea compounds and compositions for cholesterol management and related uses |
US8084498B2 (en) | 2003-12-24 | 2011-12-27 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US8975300B2 (en) | 2003-12-24 | 2015-03-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US20100137444A1 (en) * | 2003-12-24 | 2010-06-03 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US8642653B2 (en) | 2003-12-24 | 2014-02-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
US20060009487A1 (en) * | 2004-06-09 | 2006-01-12 | Sircar Jagadish C | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
US20050277690A1 (en) * | 2004-06-09 | 2005-12-15 | Sircar Jagadish C | Small molecules for treatment of hypercholesterolemia and related diseases |
US20070004644A1 (en) * | 2004-06-09 | 2007-01-04 | Sircar Jagadish C | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
US8242130B2 (en) | 2004-10-20 | 2012-08-14 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
US20090259048A1 (en) * | 2004-10-20 | 2009-10-15 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US8093273B2 (en) | 2004-10-20 | 2012-01-10 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US20060205767A1 (en) * | 2004-10-20 | 2006-09-14 | Wong Norman C | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
US20060205792A1 (en) * | 2004-10-20 | 2006-09-14 | Wong Norman C | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US20090029987A1 (en) * | 2005-07-29 | 2009-01-29 | Resverlogix Corp. | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
US8889698B2 (en) | 2007-02-01 | 2014-11-18 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
US20080188467A1 (en) * | 2007-02-01 | 2008-08-07 | Wong Norman C W | Compounds for the prevention and treatment of cardiovascular diseases |
US10532054B2 (en) | 2007-02-01 | 2020-01-14 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
US9199990B2 (en) | 2007-02-01 | 2015-12-01 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
EP2431043A1 (en) | 2007-05-23 | 2012-03-21 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption |
WO2008147807A2 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
US11407719B2 (en) | 2009-03-18 | 2022-08-09 | Resverlogix Corp. | Anti-inflammatory agents |
US10882828B2 (en) | 2009-03-18 | 2021-01-05 | Resverlogix Corp. | Anti-inflammatory agents |
US10131640B2 (en) | 2009-03-18 | 2018-11-20 | Resverlogix Corp. | Anti-inflammatory agents |
US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
WO2011027257A2 (en) | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
EP3358008A1 (en) | 2009-09-03 | 2018-08-08 | Pfizer Vaccines LLC | Pcsk9 vaccine |
US8623897B2 (en) | 2010-09-20 | 2014-01-07 | Kareus Therapeutics, Sa | Methods and compositions for treatment of diabetes and dyslipidemia |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
US9610251B2 (en) | 2011-11-01 | 2017-04-04 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US10016426B2 (en) | 2011-11-01 | 2018-07-10 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9278940B2 (en) | 2012-11-21 | 2016-03-08 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
US10925938B2 (en) | 2014-02-11 | 2021-02-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
US11696941B2 (en) | 2014-02-11 | 2023-07-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same |
US10772894B2 (en) | 2015-03-13 | 2020-09-15 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US11744816B2 (en) | 2015-03-13 | 2023-09-05 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US10912751B2 (en) | 2015-03-13 | 2021-02-09 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US11116739B2 (en) | 2015-03-16 | 2021-09-14 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease |
JP2019507150A (en) * | 2016-02-25 | 2019-03-14 | 中国科学院上海薬物研究所Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, its production method and its use |
US20190039989A1 (en) * | 2016-02-25 | 2019-02-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
US10414713B2 (en) * | 2016-02-25 | 2019-09-17 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Fatty acid compound, preparation method therefor and use therefor |
US11407705B2 (en) | 2019-06-21 | 2022-08-09 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11613511B2 (en) | 2019-06-21 | 2023-03-28 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11760714B2 (en) | 2019-06-21 | 2023-09-19 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
US11926584B2 (en) | 2019-06-21 | 2024-03-12 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3773946A (en) | Triglyceride-lowering compositions and methods | |
US3930024A (en) | Pharmaceutical compositions and methods | |
DK175544B1 (en) | Use of azithromycin and its derivatives for the preparation of antiprotozoal drugs | |
JP2525478B2 (en) | Active Vitamin D with improved stability (3) Lower solid preparation | |
DD221459A5 (en) | PROCESS FOR PREPARING OMEPRAZOLE SALTS | |
DE3318989C2 (en) | ß, gamma-dihydropolyprenyl alcohol derivatives and medicaments containing them and their use | |
CN101011372A (en) | Preparing method of alpha-ketoglutaric acid-arginine salt and its use for treating hepatic disease | |
IE51029B1 (en) | Pharmaceutical preparations containing rosmarinic acid and their use in the treatment of inflammations | |
JPH08283154A (en) | Lipid metabolism improver | |
US3144387A (en) | Anti-inflammatory compositions | |
US2753288A (en) | Scopolamine lower-alkyl halide therapeutic composition | |
CA1038402A (en) | Therapeutic agents | |
US3053892A (en) | Metaphosphoric acid complexes of tetracycline and its analogs | |
CA1256803A (en) | Pharmaceutical formulation containing azapropazone | |
IL35200A (en) | Pharmaceutical compositions containing dicarboxylic acids possessing serum triglyceride-lowering activity | |
US3362879A (en) | Tyrosine tranquilizing compositions and methods of treatment | |
EP0239332B1 (en) | A pharmaceutical formulation containing indomethacin | |
US3242235A (en) | Phytate salts of the tetracyclines | |
US3852454A (en) | Treatment of rheumatoid arthritis | |
US3501577A (en) | Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate | |
US4402943A (en) | Antihypertension treatment | |
JPH0687750A (en) | Medicine composition | |
US3772433A (en) | Treatment of hepatopathias with saccharides | |
US3538126A (en) | Anthrone oxime compounds | |
JPS5817443B2 (en) | Hyperlipidemia therapeutic agent whose main ingredient is ML-236B metal salt |